ID   CEM/C2
AC   CVCL_3497
SY   CCRF-CEM C2; CEM-C2; CEMC2
DR   BTO; BTO_0005931
DR   CLO; CLO_0002356
DR   CLDB; cl5178
DR   ATCC; CRL-2264
DR   BioSample; SAMN03471853
DR   cancercelllines; CVCL_3497
DR   Cell_Model_Passport; SIDM01250
DR   ChEMBL-Cells; CHEMBL3307952
DR   ChEMBL-Targets; CHEMBL612406
DR   Cosmic; 683535
DR   IZSLER; BS TCL 153
DR   LINCS_LDP; LCL-1035
DR   PubChem_Cell_line; CVCL_3497
DR   Wikidata; Q54809270
RX   PubMed=7579731;
RX   PubMed=12068308;
CC   Population: Caucasian.
CC   Doubling time: ~30 hours (ATCC=CRL-2264).
CC   Selected for resistance to: ChEBI; CHEBI_27656; Camptothecin (CPT).
CC   Sequence variation: Gene fusion; HGNC; HGNC:13222; BCL11B + HGNC; HGNC:2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC=CRL-2264; IZSLER=BS TCL 153
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 10,13
ST   D21S11: 31,34.2
ST   D5S818: 13
ST   D7S820: 8.3,9 (ATCC=CRL-2264)
ST   D7S820: 9 (IZSLER=BS TCL 153)
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 33
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies, Helen R.
RA   Bignell, Graham Robert
RA   Cox, Charles
RA   Stephens, Philip J.
RA   Edkins, Sarah
RA   Clegg, Sheila
RA   Teague, Jon W.
RA   Woffendin, Hayley
RA   Garnett, Mathew J.
RA   Bottomley, William
RA   Davis, Neil
RA   Dicks, Ed
RA   Ewing, Rebecca
RA   Floyd, Yvonne
RA   Gray, Kristian
RA   Hall, Sarah
RA   Hawes, Rachel
RA   Hughes, Jaime
RA   Kosmidou, Vivian
RA   Menzies, Andrew
RA   Mould, Catherine
RA   Parker, Adrian
RA   Stevens, Claire
RA   Watt, Stephen
RA   Hooper, Steven
RA   Wilson, Rebecca
RA   Jayatilake, Hiran
RA   Gusterson, Barry Austin
RA   Cooper, Colin S.
RA   Shipley, Janet M.
RA   Hargrave, Darren
RA   Pritchard-Jones, Kathryn
RA   Maitland, Norman J.
RA   Chenevix-Trench, Georgia
RA   Riggins, Gregory J.
RA   Bigner, Darell Doty
RA   Palmieri, Giuseppe
RA   Cossu, Antonio
RA   Flanagan, Adrienne Margaret
RA   Nicholson, Andrew
RA   Ho, Judy W.C.
RA   Leung, Suet Yi
RA   Yuen, Siu Tsan
RA   Weber, Barbara L.
RA   Seigler, Hilliard Foster
RA   Darrow, Timothy L.
RA   Paterson, Hugh F.
RA   Marais, Richard
RA   Marshall, Christopher John
RA   Wooster, Richard
RA   Stratton, Michael Rudolf
RA   Futreal, P. Andrew
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=7579731;
RA   Kapoor, Rohit
RA   Slade, D. Lynn
RA   Fujimori, Akira
RA   Pommier, Yves
RA   Harker, W. Graydon
RT   "Altered topoisomerase I expression in two subclones of human CEM
RT   leukemia selected for resistance to camptothecin.";
RL   Oncol. Res. 7:83-95(1995).
//